Effectiveness and Safety of Repeated Quadruple Therapy in Helicobacter pylori Infection After Failure of Second-line Quadruple Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sang Kyu | - |
dc.contributor.author | Lee, Sang Woo | - |
dc.contributor.author | Park, Jae Yeon | - |
dc.contributor.author | Kwon, Bo Sung | - |
dc.contributor.author | Kim, Seung Young | - |
dc.contributor.author | Hyun, Jong Jin | - |
dc.contributor.author | Kim, Jeong Han | - |
dc.contributor.author | Jung, Sung Woo | - |
dc.contributor.author | Koo, Ja Seol | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Choi, Jai Hyun | - |
dc.date.accessioned | 2021-09-07T07:45:48Z | - |
dc.date.available | 2021-09-07T07:45:48Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2011-10 | - |
dc.identifier.issn | 1083-4389 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/111446 | - |
dc.description.abstract | Backgrounds: Quadruple therapy using a proton-pump inhibitor, bismuth, metronidazole, and tetracycline is a standard second-line therapy for Helicobacter pylori infection, achieving an eradication rate of about 80% in Korea. A standard third-line therapy is not currently established, although various protocols have been proposed. We performed this study to evaluate the effectiveness of a retrial with quadruple therapy before starting a third-line treatment with new drugs. Materials and Methods: In 80 of 746 patients treated with a second-line quadruple therapy at the Korea University Ansan Hospital between January 2002 and September 2010, treatment for H. pylori had failed, and 45 of these patients were eligible for this study. Eradication of H. pylori was assessed by repeated endoscopy or by the C-13-urea breath test at least 4 weeks after therapy. The patients with treatment failure were treated again with quadruple regimen for 2 weeks and reevaluated for treatment effectiveness and safety. Results: The eradication rate with second-line quadruple therapy was 86.9%. Of the 80 patients who failed treatment for H. pylori with the initial second-line quadruple therapy, 64 patients were treated again with the same regimen. Of the 45 retreated patients in this study, three patients were lost to follow-up and two complied poorly with medication. The eradication rate in the 40 patients retreated was 75.0% at per-protocol analysis. Seventeen patients experienced mild adverse events. Conclusions: A retrial of quadruple therapy before use of a third-line therapy may be safe and effective for patients who fail to respond to second-line quadruple therapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | ANTIBIOTIC-RESISTANCE | - |
dc.subject | RESCUE THERAPIES | - |
dc.subject | CONSENSUS REPORT | - |
dc.subject | TRIPLE THERAPY | - |
dc.subject | METRONIDAZOLE | - |
dc.subject | ERADICATION | - |
dc.subject | MANAGEMENT | - |
dc.subject | AMOXICILLIN | - |
dc.subject | OMEPRAZOLE | - |
dc.subject | EFFICACY | - |
dc.title | Effectiveness and Safety of Repeated Quadruple Therapy in Helicobacter pylori Infection After Failure of Second-line Quadruple Therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Sang Woo | - |
dc.contributor.affiliatedAuthor | Hyun, Jong Jin | - |
dc.contributor.affiliatedAuthor | Jung, Sung Woo | - |
dc.contributor.affiliatedAuthor | Koo, Ja Seol | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Choi, Jai Hyun | - |
dc.identifier.doi | 10.1111/j.1523-5378.2011.00870.x | - |
dc.identifier.scopusid | 2-s2.0-80052987111 | - |
dc.identifier.wosid | 000295015600010 | - |
dc.identifier.bibliographicCitation | HELICOBACTER, v.16, no.5, pp.410 - 414 | - |
dc.relation.isPartOf | HELICOBACTER | - |
dc.citation.title | HELICOBACTER | - |
dc.citation.volume | 16 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 410 | - |
dc.citation.endPage | 414 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.subject.keywordPlus | ANTIBIOTIC-RESISTANCE | - |
dc.subject.keywordPlus | RESCUE THERAPIES | - |
dc.subject.keywordPlus | CONSENSUS REPORT | - |
dc.subject.keywordPlus | TRIPLE THERAPY | - |
dc.subject.keywordPlus | METRONIDAZOLE | - |
dc.subject.keywordPlus | ERADICATION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | AMOXICILLIN | - |
dc.subject.keywordPlus | OMEPRAZOLE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordAuthor | Bismuth | - |
dc.subject.keywordAuthor | quadruple therapy | - |
dc.subject.keywordAuthor | second-line therapy | - |
dc.subject.keywordAuthor | re-treatment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.